DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--QuintilesIMS (NYSE:Q) today announced that it will be changing its name
to IQVIA, a company dedicated to using analytics and science to help
healthcare stakeholders find better solutions for their patients,
effective November 6, 2017. Beginning on November 15, 2017, equity
shares of the company will trade on the NYSE under the new name and new
ticker symbol “IQV.” Until then, IQVIA will continue to be listed under
QuintilesIMS and symbol “Q” per the listing notification requirements of
the NYSE.
“Today is a defining moment for our organization as we introduce a new
name that aligns with our vision to help stakeholders drive healthcare
forward”
IQVIA’s client solutions are powered by the IQVIA CORE™. The CORE
enables IQVIA to provide customized solutions for clients leveraging the
world’s largest curated healthcare information source, advanced
analytics, leading technologies and extensive industry knowledge across
diseases, geographies and scientific methods. It fuels the company’s
approach to human data science, including faster, more predictable
clinical development, innovative approaches to generating real-world
evidence, machine learning to improve patient care, and strategies for
precision commercial engagement. The seamless integration of these
elements from molecule to market enables our customers to drive enhanced
value, access and health outcomes around the world.
“Today is a defining moment for our organization as we introduce a new
name that aligns with our vision to help stakeholders drive healthcare
forward,” said IQVIA Chairman and CEO Ari Bousbib. “Our clients have
been instrumental in our becoming IQVIA. IMS Health and Quintiles came
together because our clients were asking for better, faster ways to
bring innovations to patients and capture the improvements the industry
has been pursuing for years. Since the merger, we’ve worked to integrate
our capabilities in advanced analytics, leading technologies and
therapeutic expertise into powerful, differentiated offerings. Our
vision is to outpace the inevitable progress of change across the life
sciences and accelerate our ability to empower healthcare decision
makers to meet the future head on.”
IQVIA’s ongoing commitment to data security and privacy protection
measures and decades of deep, practical experience are critical drivers
of our global leadership. As a company, we will continue to engage in a
wide variety of governance practices and administrative, technical and
physical safeguards and controls to protect individual privacy. We work
closely with data protection authorities, trusted third parties and
privacy experts around the world to ensure we are diligent in the
protection of individual privacy.
More information about IQVIA can be found at www.IQVIA.com
and this video link: http://bit.ly/2lSbrhn.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of information, innovative
technology solutions and contract research services focused on using
data and science to help healthcare clients find better solutions for
their patients. Formed through the merger of IMS Health and Quintiles,
IQVIA offers a broad range of solutions that harness advances in
healthcare information, technology, analytics and human ingenuity to
drive healthcare forward. IQVIA enables companies to rethink approaches
to clinical development and commercialization, innovate with confidence
as well as accelerate meaningful healthcare outcomes. IQVIA has
approximately 55,000 employees in more than 100 countries, all committed
to making the potential of human data science a reality. IQVIA’s
approach to human data science is powered by the IQVIA CORE™, driving
unique actionable insights at the intersection of big data,
transformative technology and analytics with extensive domain expertise.
IQVIA is a global leader in protecting individual patient privacy. The
company uses a wide variety of privacy-enhancing technologies and
safeguards to protect individual privacy while generating and analyzing
the information that helps their customers drive human health outcomes
forward. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap into a
deeper understanding of diseases, human behaviors and scientific
advances, in an effort to advance their path toward cures. To learn
more, visit www.IQVIA.com.
IQVIAFIN
Contacts
IQVIA Investor Relations
Andrew Markwick, +1-973-257-7144
andrew.markwick@iqvia.com
or
IQVIA
Media Relations
Tor Constantino, +1-484-567-6732
tor.constantino@iqvia.com